JONG IN LEE

Dr. JONG IN LEE

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KRKi-Jong Rhee
Ki-Jong Rhee
JLJONG IN LEE
JONG IN LEE
YEYoung Woo Eom
Young Woo Eom
Mesenchymal stem cells (MSCs) can exhibit a marked tropism towards site of tumors. Many studies have reported that tumor progression and metastasis increase by MSCs. In contrast, other studies have shown that MSCs suppress growth of tumors. MSCs contribute to tumor growth promotion by several mechanisms: (1) transition to tumor-associated fibroblasts; (2) suppression of immune response; (3) promotion of angiogenesis; (4) stimulation of epithelial-mesenchymal transition (EMT); (5) contribution to the tumor microenvironment; (6) inhibition of tumor cell apoptosis; and (7) promotion of tumor metastasis. In contrast to the tumor-promoting properties, MSCs inhibit tumor growth by increasing inflammatory infiltration, inhibiting angiogenesis, suppressing Wnt signaling and AKT signaling, and inducing cell cycle arrest and apoptosis. In this review, we will discuss potential mechanisms by which MSC mediates tumor support or suppression and then the possible tumor-specific therapeutic strategies using MSCs as delivery vehicles, based on their homing potential to tumors.

11 August 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
SHShin Young Hyun
Shin Young Hyun
ENEun Jung Na
Eun Jung Na
JJJi Eun Jang
Ji Eun Jang
HCHaerim Chung
Haerim Chung
SKSoo-Jeong Kim
Soo-Jeong Kim
JCJune-Won Cheong
June-Won Cheong
Objective: Myeloid‐derived suppressor cells (MDSCs) facilitate tumor growth and development by suppressing T cell function; however, their role in acute myeloid leukemia (AML) remains unclear. Here, we investigated the immunosuppressive role and prognostic value of blasts with an MDSC‐like phenotype.Methods: CD11b+CD33+HLA‐DR− MDSC‐like blasts from bone marrow mononuclear cells of patients with AML were analyzed. To investigate their T cell‐suppressing function, MDSC‐like blasts were isolated using flow cytometry and co‐cultured with CD8+ cytotoxic T cells and NB4 leukemic cells. Treatment outcomes were then compared between the MDSC‐like blasts low (≤9.76%) and high (>9.76%) groups to identify clinical significance.Results: MDSC‐like blasts showed higher expression of arginase‐1 and inducible nitric oxide synthase. Isolated MDSC‐like blasts significantly suppressed CD8+ T cell proliferation induced by phytohemagglutinin A. NB4 cell proliferation was significantly suppressed upon co‐culture with CD8+ cytotoxic T cells and partially restored upon co‐culture with MDSC‐like blasts. Patients with high MDSC‐like blasts at diagnosis showed substantially shorter overall survival and leukemia‐free survival relative to low MDSC‐like blasts patients, with subgroup analysis showing statistically significant differences in patients not receiving allogeneic hematopoietic stem cell transplantation.Conclusion: We demonstrated that MDSC‐like blasts drive AML‐specific immune‐escape mechanisms by suppressing T cell proliferation and restoring T cell‐suppressed NB4 cell proliferation, with clinically higher fractions of MDSC‐like blasts at diagnosis resulting in poor prognosis.

1 January 2011 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YEYoung Woo Eom
Young Woo Eom
Jong Eun LeeJong Eun Lee
Jong Eun Lee
MYMal Sook Yang
Mal Sook Yang
IJIn Keun Jang
In Keun Jang
HKHyo Eun Kim
Hyo Eun Kim
HKHyun-Soo Kim
Hyun-Soo Kim
Eom YW, et al. Yonsei Med J. 2011 Nov;52(6):999-1007. http://dx.doi.org/10.3349/ymj.2011.52.6.999

5 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Soohyeon LeeSoohyeon Lee
Soohyeon Lee
SISeock-Ah Im
Seock-Ah Im
GKGun Min Kim
Gun Min Kim
KJKyung Hae Jung
Kyung Hae Jung
SKSeok Yun Kang
Seok Yun Kang
Yeon Hee 박연희 ParkYeon Hee 박연희 Park
Yeon Hee 박연희 Park
In the era of CDK4/6 inhibitors in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, few trials have been specifically studied to compare quality of life between palbociclib plus endocrine therapy (ET) and cytotoxic chemotherapy exclusively in premenopausal women. We aimed to evaluate differences of patient report outcomes (PROs) between palbociclib plus ET and capecitabine. PROs were assessed using EORTC QLQ-C30 at baseline, every 6 weeks, and the end of treatment. All EORTC QLQ-30 scores were maintained from baseline to the end of treatment. Patients treated palbociclib plus ET arm experienced delay in time-to-deterioration of physical functioning (HR = 0.58, 95% CI, 0.36 to 0.84, p = 0.0058), nausea and vomiting (HR = 0.48; 95% CI, 0.32 to 0.73, p = 0.0005), and diarrhea (HR = 0.42; 95% CI, 0.27 to 0.65, p = 0.001). There was a numeric trend for worsening of insomnia (HR = 1.43; 95% CI, 0.96 to 2.16, p = 0.079) and favoring of appetite loss (HR = 0.69, 95% CI, 0.44 to 1.07, p = 0.09) in the palbociclib plus ET arm. Premenopausal patients with palbociclib plus ET maintained QoL without compromising treatment efficacy.

1 January 2020 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YKYundeok Kim
Yundeok Kim
HJHoi-Kyung Jeung
Hoi-Kyung Jeung
JCJune-Won Cheong
June-Won Cheong
JSJaewoo Song
Jaewoo Song
SBSoo Han Bae
Soo Han Bae
YMYoo Hong Min
Yoo Hong Min
Kim Y, et al. Yonsei Med J. 2020 Sep;61(9):762-773. https://doi.org/10.3349/ymj.2020.61.9.762

7 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SHSeok Hahn
Seok Hahn
KKKwangmin Kim
Kwangmin Kim
MKMin-Ju Kim
Min-Ju Kim
HCHyang-Suk Choi
Hyang-Suk Choi
HNHany Noh
Hany Noh
AHAiri Han
Airi Han
Breast cancer is a leading cause of death worldwide. Tumor vascularity and immune disturbances are hallmarks of cancer. This study aimed to investigate the reciprocal effect of tumor vascularity, assessed by the tumor-to-aorta ratio (TAR) of Hounsfield units (HU) on computed tomography (CT), and host immunity, represented by the serum neutrophil-to-lymphocyte ratio (NLR) from peripheral, complete blood cell counts and its impact on patient survival. Female patients with breast cancer who received primary treatment between 2003 and 2018 at Wonju Severance Hospital, Korea, were included. The final cohort included 740 patients with a mean age of 54.3 ± 11.3 (22–89) years. The TAR was 0.347 ± 0.108 (range, 0.062–1.114) and the NLR was 2.29 ± 1.53 (0.61–10.47). The cut-off value for the TAR and NLR were 0.27 and 1.61, respectively. The patients with a TAR > 0.27 showed a poor recurrence free-interval (RFI) only when their NLR was larger than 1.61, and vice versa. The patients showed worse RFI when they had both high TAR and NLR. Our results suggest a dynamic reciprocal communication between tumor vascularity and systemic immunity.